We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prevalence and Clinical Outcome of FMS -Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor--Acute Myeloid Leukemia: Systematic Review and Meta-Analysis.
- Authors
Srinivasan, Shyam; Kumar, Shathish; Vijayasekharan, Kalasekhar; Agrawal, Amit Kumar
- Abstract
This meta-analysis was undertaken to study the prevalence of FMS-Like tyrosine kinase (FLT3) mutations amongst patients with core binding factor-Acute myeloid leukemia (CBF-AML). 22 studies including 2,787 patients with CBF-AML were included in this meta-analysis. Overall prevalence of FLT3 mutation among CBF-AML was estimated as 13%. FLT3-ITD mutations was more prevalent amongst t(8;21) while FLT3-TKD mutations was more prevalent among Inv(16). Understanding the prevalence and prognostic significance of FLT3 mutations among CBF-AML will help in better risk stratification and in guiding treatment. Background: Core binding factor acute myeloid leukemia (CBF-AML) belongs to favorable risk group in AML. However, approximately 50% of patients with CBF-AML remain incurable and their outcomes are also determined by the various co-occurring mutations. Though, FMS-like tyrosine kinase-3(FLT3) mutation in AML is associated with poor survival, the prevalence and prognostic significance of FLT3 mutations among CBF-AML is unknown. Patients and Methods: We performed a systematic review and meta-analysis to assess the prevalence of FLT3 mutations (ITD and TKD) among patients with CBF-AML. The pooled prevalence of FLT3 mutations was estimated for patients with CBF-AML, t(8;21) and Inv(16). Pooled odds ratio was calculated to compare the prevalence of various FLT3 mutations within the 2 subsets of CBF-AML. A random effects model was adopted for analysis when heterogenicity existed (P[sub heter]o[sub g]e[sub nicity] < 0.05 or I[2]> 50%). Otherwise, a fixed effects model was used. Results: The pooled prevalence of any FLT3 mutations among patients with CBF-AML was available from 18 studies and was 13% (95% CI: 10%-16%; I[2] = 79%). Comparison of prevalence of FLT3 mutations between the 2 subgroups of CBF-AML showed that patients with t(8;21) had a higher prevalence of FLT3-ITD [pooled odds ratio(OR): 2.23 (95% CI:1.41-3.53, P < .01)] and lower prevalence of FLT3-TKD [pooled OR: 0.29 (95% CI:0.19-0.44; P < .01)] compared to patients with Inv(16). Additionally, we have discussed the prognostic significance of FLT3 mutations in CBF-AML patients. Conclusion: The prevalence of FLT3-TKD mutation was commoner among Inv(16) AML while FLT3-ITD mutation was commoner among t(8;21) AML. Uniform reporting of outcomes is essential to understand the prognostic significance of FLT3 mutations among CBF-AML.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2022, Vol 22, Issue 4, pe221
- ISSN
2152-2650
- Publication type
Article
- DOI
10.1016/j.clml.2021.09.020